Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Briacell Therapeutics Corp T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.


TSX:BCT - Post by User

Bullboard Posts
Post by Vacc77on Nov 15, 2016 1:04pm
127 Views
Post# 25463591

Briavax

BriavaxThe update was great: BRIAVAX in december (1 month) will EXIST. We are safely going forward and adding value. Think...if you are a big pharma...you would have to pay much more now with a 2016 newly manufactured up to date vaccine, secure and tested. With a trial already approved by FDA and impressive phase 1 results. The testing in NR shows excellent results.

This stock has low volume and is actually easily manipulated down because people on the know want take your shares for cheap.

We are actually adding huge value and be prepared to fast track approval if the next trial shows same lesion regression. It's unethical to hold a life saving trestment...Trump knows it.

If you are looking for an Homerun on first inning, this stock is maybe not for you. 

There Will be a PR before the end of december.

vacc

Bullboard Posts